### DRUG DRIVING IN EUROPE:

#### POLICY MEASURES FOR NATIONAL AND EU ACTION

E T S C

LAURENCE ATCHISON
SENIOR RESEARCHER, PACTS









### INTRODUCTION

- What do we mean by psychoactive drugs?
  - Illicit and Licit (medicines)
- Psychoactive drugs have a negative effect on the ability to drive
  - Cognitive behaviour
  - Psychomotor functioning



- Drug driving is not as well understood as drink driving
  - A wide variety of substances: illicit and licit, established and emerging
  - Less prevalent than drink driving: less information
- Our knowledge is growing, but still limited
  - Need more knowledge of drug driving and how to prevent it



### HOW MANY PEOPLE ARE USING DRUGS?

#### General Population:

25% of 15-64 year olds in EU have tried illicit drugs at some point

#### Driving population:

- I.9% used illicit drugs/I.36% used licit drugs
- Self reporting figures are higher:
  - I 1% said they had driven after using illicit drugs at least once in past year
  - 22% said they had driven after using medication (with a driving warning)

#### What factors affect this?


Age/Gender





FIG. 2

Self-declared behaviour as a road user having driven under the influence of drugs, by country (% of at least once within the last 12 months).<sup>26</sup>



(Achermann Sturmer, Y. (2016). Driving under the influence of alcohol and drugs. ESRA thematic report no.2. ESRA project (European Survey of Road users' safety attitude). Bern, Switzerland: Swiss Council for Accident Prevention, p22.)



# HOW MANY KILLED AND SERIOUSLY INJURED DRIVERS HAD USED DRUGS?

#### **TABLE 3**

Use of alcohol among drivers seriously injured or killed in Europe

	Range (seriously injured)	Range (killed)
Alcohol	14.1 - 30.2%	15.6 - 38.9%

#### **TABLE 4**

Use of illicit drugs among drivers seriously injured or killed in Europe

Illicit drug groups	Range (seriously injured)	Range (killed)
THC (and/or THC-COOH)	0.5 - 2.2%	0.0 - 1.8%
Cocaine (and/or benzoylecgonine)	0.0 - 1.3%	0.0 - 0.0%
Amphetamines	0.0 - 1.1%	0.0 - 2.1%
Illicit opiods	0.0 - 0.7%	0.0 - 0.0%

#### TABLE 5

Use of medicines among drivers seriously injured or killed in Europe

Medicine groups	Range (seriously injured)	Range (killed)
Benzodiazepines	0.0 - 2.3%	0.0 - 5.2%
Medicinal opioids	0.0 - 5.7%	0.6 - 1.5%
Z-drugs	0.0 - 2.1%	0.0 - 2.8%

#### TABLE 6

Use of combinations of substances among drivers injured and killed in Europe <sup>43</sup>

Combinations	Range (seriously injured)	Range (killed)
Alcohol with drugs and/or medicines	2.3 - 13.2%	4.3 - 7.9%
Combinations of drugs and/ or medicines	0.5 - 4.3%	0.4 - 7.3%

(EMCDDA 2012, Driving Under the Influence of Drugs, Alcohol and Medicines in Europe: Findings from the DRUID Project, pp. 16-17.)



# COUNTERMEASURE AREAS 1. LEGISLATION AND ENFORCEMENT 1/2

### I. Legal limits/'per se' laws

 Establish a fixed substance limit – similar to BAC levels. Any driver detected with a substance reaching or exceeding the legal limit is considered to have broken the law.

#### II. Zero tolerance laws

Set legal limits with a concentration set at the lab limit of detection. Any driver with a
detectable amount of a relevant substance is considered to have broken the law.

### III. Impairment legislation

In each case it must be proven that the skills of the driver were adversely affected by a specific drug. Signs of impairment are usually observed and recorded by the police when they stop a driver.



## COUNTERMEASURE AREAS I. LEGISLATION AND ENFORCEMENT 2/2

- Penalties
  - Withdrawal of the licence
  - Fines
  - Prison



- Up to 6 months in prison
- Minimum one-year ban
- Enforcement
  - Penalties need to be enforced
    - Roadside screening
    - Post-collision forensic testing

- Detection and Technology
  - Accurate, reliable and widespread
  - Roadside screening/ lab/conformation tests
  - Variety of limits that can be set
    - Laboratory limit of detection.
    - Risk thresholds/lower effect limits
    - Impairment limits
    - Supratherapeutic limits (for medicines).



## COUNTERMEASURE AREAS 2. EDUCATION AND CAMPAIGNS

- In school, the workplace and in public
- Targeting high risk groups
  - Young people (school, social media)
  - Males
- Helps to increase social disapproval
- Education for professionals particularly important
  - Healthcare/policymakers/legislators/judiciary











# COUNTERMEASURE AREAS 3. REHABILITATION AND HEALTHCARE

- Drink driving schemes used a basis
  - Shown to be effective and reduce recidivism
  - Help restore mobility in a safe way
  - Little evaluation of drug driving schemes
- Healthcare strategies
  - Dealing with general drug use
  - Relationship between medical professionals and licensing authorities
    - Who is responsible?



- Four three-hour classes
- €430
- Must complete to regain licence
- Forbidden to pass on information
- Compulsory to pass on information
- Drug dependent drivers must pass on themselves







# RECOMMENDATIONS I. LEGISLATION AND ENFORCEMENT

- A zero tolerance system for illicit psychoactive drugs
- Consider the potential ramifications of drug legalisation on drug driving
- Development by the EC of common standards for roadside drug driving enforcement
- Ensure police forces are properly trained in when and how to perform drug screening



# RECOMMENDATIONS 2. EDUCATION AND CAMPAIGNS

- Incorporate drug driving education into school based road safety initiatives, along side drink driving education
- Target education and campaigns at high risk groups
  - Young males
- Incorporate the issues relating to psychoactive drugs and their effects into professional driver education



## RECOMMENDATIONS 3. REHABILITATION PROGRAMMES

- Integrate rehabilitation schemes in the national countermeasures system
  - Drug offenders should be treated separately from alcohol offenders
  - Distinguish between non-addicts and addicts
- Assessment and rehabilitation should be regulated according to criteria/common standards
- Licence reacquisition for known drug users could be regulated
  - Different approaches across Europe



# RECOMMENDATIONS 4. RESEARCH AND DATA COLLECTION

- Research into the effects of common psychoactive drugs on driving behaviour must continue
  - Countermeasures must remain fit-for-purpose and keep in line with evolving drug use and drug driving behaviours
- Research into the effects of new psychoactive substances on driving behaviours
- Research into the effectiveness of countermeasures
- Continue investing in development of detection technology
- Encourage greater and improved monitoring of drug use in traffic
  - Standardises monitoring methods
  - Standardise and maximise post-collision data collection.



### Laurence Atchison, Senior Researcher, PACTS, UK laurence.atchison@pacts.org.uk

- Francisco Alonso, INTRAS, Institute of Traffic and Road Safety, University of Valencia, Spain
- Ilona Butler, Motor Transport Institute Poland
- Sjoerd Houwing, Institute for Road Safety Research, SWOV, Member of the Scientific Advisory Board, the Netherlands
- Jacqueline Lacroix, Head of Traffic Medicine and International Affaris, German Road Safety Council
- Gerry Peeters, Belgian Federal Highway Police
- Dr. Charles Mercier Guyon, Medical Advisor of La Prevention Routiere France
- Alain Verstraete, Department of Clinical Chemistry, Microbiology and Immunology, University of Ghent
- Kim Wolff, Professor of Addiction Science, Department of Pharmacy and Forensic Science, Faculty of Medicine & Life Sciences, King's College, London, UK



### THANKS FOR LISTENING



LAURENCE.ATCHISON@PACTS.ORG.UK